Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy

Ishimaru, Kotaro; Takano, Atsushi; Katsura, Motoyasu; Yamaguchi, Nimpei; Kaneko, Ken-ichi; Takahashi, Haruo

추천

검색

자료유형: 학술저널

저자정보: Ishimaru, Kotaro (Department of Otolaryngology, Nagasaki University Hospital) Takano, Atsushi (Department of Otolaryngology, Nagasaki University Hospital) Katsura, Motoyasu (Department of Otolaryngology, Nagasaki University Hospital) Yamaguchi, Nimpei (Department of Otolaryngology, Nagasaki University Hospital) Kaneko, Ken-ichi (Department of Otolaryngology, Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences) Takahashi, Haruo (Department of Otolaryngology, Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제22호

발행연도: 2014.1

수록면: 9,627 - 9,630 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic regimen comprising granisetron ($40{\mu}g/kg$ on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin $20mg/m^2$ on days 1-4; 5-FU $400mg/m^2$ on days 1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group showed significantly better results, including a higher rate of complete response (no vomiting and no salvage therapy) for the acute phase (p=0.0342), although there was no marked difference between the two groups with regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant is safe and effective for HNC patients receiving daily cisplatin therapy.

#aprepitant #cisplatin #antiemetic #head and neck cancer #CINV

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요